Key Takeaways IRWD stock jumped 26.7% on Jan. 2 after the company issued upbeat revenue guidance for 2026.Ironwood expects $450-$475M in 2026 revenues and more than $300M in adjusted EBITDA.IRWD to start a phase III study on apraglutide in 1H26 after aligning with the FDA on study design.Shares of Ironwood Pharmaceuticals (IRWD) were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026. The company maintained its revenue guidance for full-year 2025, which it had provided in Novemb ...